OBJECTIVES: The extent to which highly active antiretroviral therapy (HAART) era cognitive disorders are due to active processes, incomplete clearance of reservoirs, or comorbidities is controversial. This study aimed to determine if immunologic and virologic factors influence cognition after first-time HAART in Thai individuals with HIV-associated dementia (HAD) and Thai individuals without HAD (non-HAD). METHODS: Variables were captured longitudinally to determine factors predictive of degree of cognitive recovery after first-time HAART. Neuropsychological data were compared to those of 230 HIV-negative Thai controls. RESULTS: HIV RNA and CD4 lymphocyte counts were not predictive of HAD cross-sectionally or degree of cognitive improvement longitudinally. In contrast, baseline and longitudinal HIV DNA isolated from monocytes correlated to cognitive performance irrespective of plasma HIV RNA and CD4 lymphocyte counts pre-HAART (p < 0.001) and at 48 weeks post HAART (p < 0.001). Levels exceeding 3.5 log(10) copies HIV DNA/10(6) monocyte at baseline distinguished all HAD and non-HAD cases (p < 0.001). At 48 weeks, monocyte HIV DNA was below the level of detection of our assay (10 copies/10(6) cells) in 15/15 non-HAD compared to only 4/12 HAD cases, despite undetectable plasma HIV RNA in 26/27 cases. Baseline monocyte HIV DNA predicted 48-week cognitive performance on a composite score, independently of concurrent monocyte HIV DNA and CD4 count (p < 0.001). CONCLUSIONS: Monocyte HIV DNA level correlates to cognitive performance before highly active antiretroviral therapy (HAART) and 48 weeks after HAART in this cohort and baseline monocyte HIV DNA may predict 48-week cognitive performance. These findings raise the possibility that short-term incomplete cognitive recovery with HAART may represent an active process related to this peripheral reservoir.
OBJECTIVES: The extent to which highly active antiretroviral therapy (HAART) era cognitive disorders are due to active processes, incomplete clearance of reservoirs, or comorbidities is controversial. This study aimed to determine if immunologic and virologic factors influence cognition after first-time HAART in Thai individuals with HIV-associated dementia (HAD) and Thai individuals without HAD (non-HAD). METHODS: Variables were captured longitudinally to determine factors predictive of degree of cognitive recovery after first-time HAART. Neuropsychological data were compared to those of 230 HIV-negative Thai controls. RESULTS: HIV RNA and CD4 lymphocyte counts were not predictive of HAD cross-sectionally or degree of cognitive improvement longitudinally. In contrast, baseline and longitudinal HIV DNA isolated from monocytes correlated to cognitive performance irrespective of plasma HIV RNA and CD4 lymphocyte counts pre-HAART (p < 0.001) and at 48 weeks post HAART (p < 0.001). Levels exceeding 3.5 log(10) copies HIV DNA/10(6) monocyte at baseline distinguished all HAD and non-HAD cases (p < 0.001). At 48 weeks, monocyte HIV DNA was below the level of detection of our assay (10 copies/10(6) cells) in 15/15 non-HAD compared to only 4/12 HAD cases, despite undetectable plasma HIV RNA in 26/27 cases. Baseline monocyte HIV DNA predicted 48-week cognitive performance on a composite score, independently of concurrent monocyte HIV DNA and CD4 count (p < 0.001). CONCLUSIONS: Monocyte HIV DNA level correlates to cognitive performance before highly active antiretroviral therapy (HAART) and 48 weeks after HAART in this cohort and baseline monocyte HIV DNA may predict 48-week cognitive performance. These findings raise the possibility that short-term incomplete cognitive recovery with HAART may represent an active process related to this peripheral reservoir.
Authors: Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor Journal: J Neurovirol Date: 2003-04 Impact factor: 2.643
Authors: J L McDermott; A A Giri; I Martini; M Bono; M Giacomini; A Campelli; L Tagliaferro; A Cara; O E Varnier Journal: J Clin Microbiol Date: 1999-07 Impact factor: 5.948
Authors: J C McArthur; D R Hoover; H Bacellar; E N Miller; B A Cohen; J T Becker; N M Graham; J H McArthur; O A Selnes; L P Jacobson Journal: Neurology Date: 1993-11 Impact factor: 9.910
Authors: Kevin R Robertson; Marlene Smurzynski; Thomas D Parsons; Kunling Wu; Ronald J Bosch; Julia Wu; Justin C McArthur; Ann C Collier; Scott R Evans; Ron J Ellis Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: V Valcour; C Shikuma; B Shiramizu; M Watters; P Poff; O Selnes; P Holck; J Grove; N Sacktor Journal: Neurology Date: 2004-09-14 Impact factor: 9.910
Authors: K C Williams; S Corey; S V Westmoreland; D Pauley; H Knight; C deBakker; X Alvarez; A A Lackner Journal: J Exp Med Date: 2001-04-16 Impact factor: 14.307
Authors: Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott Journal: AIDS Date: 2011-01-14 Impact factor: 4.177
Authors: Tricia H Burdo; Allison Weiffenbach; Steven P Woods; Scott Letendre; Ronald J Ellis; Kenneth C Williams Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Jibreel Jumare; Sara Sunshine; Hayat Ahmed; Samer S El-Kamary; Laurence Magder; Laura Hungerford; Tricia Burdo; Lindsay M Eyzaguirre; Anya Umlauf; Mariana Cherner; Alash'le Abimiku; Man Charurat; Jonathan Z Li; William A Blattner; Walter Royal Journal: J Neurovirol Date: 2017-02-27 Impact factor: 2.643
Authors: Dionna W Williams; Mike Veenstra; Peter J Gaskill; Susan Morgello; Tina M Calderon; Joan W Berman Journal: Curr HIV Res Date: 2014 Impact factor: 1.581
Authors: Cecilia M Shikuma; Louie Mar A Gangcuangco; Deirdre A Killebrew; Daniel E Libutti; Dominic C Chow; Beau K Nakamoto; Chin Yuan Liang; Cris I P Milne; Lishomwa C Ndhlovu; Jason D Barbour; Bruce T Shiramizu; Mariana Gerschenson Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731